You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 17, 2025

Drug Price Trends for TAYSOFY


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for TAYSOFY

Average Pharmacy Cost for TAYSOFY

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
TAYSOFY 1 MG-20 MCG CAPSULE 65162-0558-16 0.79458 EACH 2025-01-22
TAYSOFY 1 MG-20 MCG CAPSULE 65162-0558-58 0.79458 EACH 2025-01-22
TAYSOFY 1 MG-20 MCG CAPSULE 65162-0558-16 0.73663 EACH 2024-12-18
TAYSOFY 1 MG-20 MCG CAPSULE 65162-0558-58 0.73663 EACH 2024-12-18
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Market Analysis and Price Projections for Taysofy

Introduction

Taysofy, launched by Amneal Pharmaceuticals, is an AB-rated generic equivalent for the oral contraceptive brand Taytulla®. This analysis will delve into the market dynamics, competitive landscape, and price projections for Taysofy.

Market Context

The pharmaceutical industry, particularly the generic drug market, is highly competitive and influenced by various factors such as regulatory approvals, market exclusivity, and pricing strategies.

Generic Drug Market

Generic drugs, like Taysofy, enter the market after the patent and market exclusivity periods of the brand-name drugs expire. This allows for lower-cost alternatives, increasing accessibility for patients. The launch of Taysofy follows the approval of its Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA)[5].

Competitive Landscape

The oral contraceptive market is crowded with both brand-name and generic products. Taysofy competes directly with Taytulla® and other generic equivalents.

U.S. Annual Sales

In the 12 months ended June 2021, U.S. annual sales for Taytulla® and its generic equivalents were approximately $124.4 million. This indicates a significant market size for oral contraceptives, providing a substantial revenue potential for Taysofy[5].

Pricing Strategies

Pricing for generic drugs is generally lower than for brand-name drugs due to the absence of research and development costs and the competitive nature of the generic market.

Price Projections

Given the competitive landscape, the price of Taysofy is expected to be lower than that of Taytulla®. Here are some key points to consider:

  • Generic Pricing: Generic drugs typically offer significant cost savings compared to their brand-name counterparts. For example, generic versions of drugs can be 70-80% cheaper than the brand-name versions[3].
  • Market Dynamics: The overall drug price inflation rate is projected to be 0.00% for the period from January 1, 2025, to December 31, 2025, according to the Vizient Pharmacy Market Outlook. This suggests a stable pricing environment for pharmaceuticals, including generics like Taysofy[4].

Regulatory Environment

The regulatory environment plays a crucial role in the pricing and availability of generic drugs.

Market Exclusivity

Brand-name drug manufacturers enjoy a 12-to-16-year window of market exclusivity, which protects them from generic competition. Once this period ends, generic manufacturers like Amneal can enter the market with their own versions, leading to increased competition and lower prices[3].

Financial Projections

While specific financial projections for Taysofy are not available, we can infer from industry trends and the performance of similar generic drugs.

Revenue Potential

Given the $124.4 million in annual sales for Taytulla® and its generic equivalents, Taysofy has the potential to capture a significant share of this market. The revenue will depend on factors such as market penetration, pricing strategy, and competition from other generic versions.

Key Takeaways

  • Market Size: The oral contraceptive market is substantial, with annual sales of over $124 million for Taytulla® and its generics.
  • Pricing: Taysofy is expected to be priced lower than Taytulla®, aligning with typical generic drug pricing strategies.
  • Regulatory Environment: The end of market exclusivity for brand-name drugs allows generic manufacturers to enter the market, increasing competition and reducing prices.
  • Financial Projections: Taysofy has significant revenue potential, though exact figures depend on market dynamics and competitive strategies.

FAQs

  1. What is Taysofy? Taysofy is an AB-rated generic equivalent for the oral contraceptive brand Taytulla®, launched by Amneal Pharmaceuticals.

  2. How does Taysofy compete in the market? Taysofy competes with Taytulla® and other generic equivalents in the oral contraceptive market, offering a lower-cost alternative.

  3. What are the price projections for Taysofy? Given the generic nature of Taysofy, it is expected to be priced lower than Taytulla®, with prices influenced by the overall stable pricing environment in the pharmaceutical sector.

  4. What is the revenue potential for Taysofy? The revenue potential for Taysofy is significant, given the substantial market size for oral contraceptives, with annual sales exceeding $124 million for Taytulla® and its generics.

  5. How does the regulatory environment impact Taysofy? The regulatory environment, particularly the end of market exclusivity for brand-name drugs, allows generic manufacturers like Amneal to enter the market, increasing competition and reducing prices.

Sources

  1. Amneal Pharmaceuticals Launches Taysofy™ – Generic for Taytulla® - RXinsider[5]
  2. Market Exclusivity and U.S. Prescription Drugs - Commonwealth Fund[3]
  3. Pharmacy Market Outlook Summer 2024 - Vizient Inc.[4]

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.